Mon, Mar 2, 2015, 10:55 AM EST - U.S. Markets close in 5 hrs 5 mins


% | $
Quotes you view appear here for quick access.

Momenta Pharmaceuticals Inc. Message Board

  • ding_king2000 ding_king2000 Feb 28, 2013 5:32 PM Flag

    Comment from Momenta's management in tonight's filing:

    There are a number of factors that make it difficult for us to predict the magnitude of future Enoxaparin Sodium Injection product revenue, including the impact of generic competition on the Sandoz market share; the pricing of products that compete with Enoxaparin Sodium Injection and other actions taken by our competitors; the inventory levels of Enoxaparin Sodium Injection maintained by wholesalers, distributors and other customers; the frequency of re-orders by existing customers and the change in estimates for product reserves. Accordingly, our Enoxaparin Sodium Injection product revenue in previous quarters may not be indicative of future Enoxaparin Sodium Injection product revenue. The change in Sandoz contractual payment terms, along with additional generic competition, has caused and we expect will continue to cause our future product revenue from Enoxaparin Sodium Injection to be significantly reduced compared to revenues earned during the product's exclusivity period.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
13.93+0.28(+2.05%)10:54 AMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.